New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
09:21 EDTSUPN, TCAP, CALL, EXAS, ICPT, TIPT, HCLP, SOL, DNDN, ANF, INSY, FRF, FLO, NOAH, CNAT, KATEOn The Fly: Pre-market Movers
HIGHER: Intercept (ICPT), up 46% after upgraded at Leerink and Citigroup following OCA data. Conatus Pharmaceuticals (CNAT), which also develops treatments for liver disease, up 8.5%... Fontegra Financial (FRF), up 40% after Tiptree Financial (TIPT) to acquire the company for $10.00 per share in cash... Insys Therapeutics (INSY), up 15.4% after submiting NDA for new formula of Dronabinol Oral Solution, saying it is on track to submit at least four IND applications with the FDA in the second half of 2014... Exact Sciences (EXAS), up 8% after announcing FDA approved for Cologuard... Abercrombie & Fitch (ANF), up 2.7% after upgraded at Stifel. UP AFTER EARNINGS: Kate Spade (KATE), up 5.5%... Noah Holdings (NOAH), up 3%... ReneSola (SOL), up 5%... Supernus (SUPN), up 14%. LOWER: NII Holdings (NIHD), down 54.5% after warning it needs to make "key decisions" to address liquidity, "likely" to file a voluntary petition for relief under Chapter 11 of the Bankruptcy Code... Dendreon (DNDN), down 23.6% after warning that its alternatives could leave shareholders with no ownership... magicJack (CALL), down 10.3%, downgraded at Canaccord following Q2 results... Hi-Crush Partners (HCLP), down 4.7% after filing to sell 3.26M common units representing limited partners... Triangle Capital (TCAP), down 3.8% after filing to sell 4M shares of common stock. DOWN AFTER EARNINGS: Nuance (NUAN), down 9.4%... Flowers Foods (FLO), down 7.8%.
News For KATE;ANF;ICPT;CNAT;DNDN;EXAS;NOAH;SOL;CALL;FLO;HCLP;TCAP;FRF;TIPT;SUPN;INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 21, 2015
09:58 EDTICPTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Alibaba (BABA) initiated with an Outperform at Bernstein... Alkermes (ALKS) initiated with an Overweight at Barclays... Burlington Stores (BURL) initiated with an Outperform at FBR Capital... Crocs (CROX) initiated with a Neutral at B. Riley... Darling (DAR) initiated with a Buy at Roth Capital... Dynegy (DYN) initiated with an Outperform at RBC Capital... Esperion (ESPR) initiated with an Overweight at Barclays... Five Below (FIVE) initiated with a Market Perform at FBR Capital... Intercept (ICPT) initiated with an Overweight, $450 target at Barclays... Johnson Matthey (JMPLY) initiated with a Buy at Jefferies... Nike (NKE) initiated with a Buy at Jefferies... RTI Surgical (RTIX) initiated with a Buy at Sidoti... TeleNav (TNAV) initiated with an Outperform at Northland... Trevena (TRVN) initiated with an Equal Weight at Barclays... Vectrus (VEC) initiated with a Hold at Stifel.
05:41 EDTICPTIntercept initiated with an Overweight, $450 target at Barclays
Subscribe for More Information
05:37 EDTICPTAlkermes initiated with an Overweight at Barclays
Subscribe for More Information
May 20, 2015
13:10 EDTINSYInsys Therapeutics weakness a buying opportunity, says RBC Capital
Subscribe for More Information
12:25 EDTINSYInsys Therapeutics drops following arrest of Alabama doctors
Shares of Insys Therapeutics (INSY) are sharply lower in early afternoon trading after FOX10 News in Alabama reported that Dr. John Patrick Couch and Dr. Xiulu Ruan of Physicians' Pain Specialists of Alabama Pain Center have been arrested on drug and fraud charges. Previously, the Southern Investigative Reporting Foundation stated that Ruan and Couch were the leading prescription writers of Subsys, which is Insys' sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients, by an "impressive margin." Shares of Insys are down 8.4% to $54.76 in afternoon trading following the news of the arrests of the doctors. Reference Link
12:18 EDTINSYInsys Therapeutics puts active on sharp pullback
Insys Therapeutics June 50 and 55 puts are active on total put volume of 6,500 contracts (100 calls). June put option implied volatility is at 76, July is at 60 compared to its 90-day average of 62. Active put volume suggests traders taking positions for large upside price movement.
10:11 EDTCNATConatus management to meet with SunTrust
Subscribe for More Information
08:05 EDTINSYInsys Therapeutics pipeline growing, underappreciated, says RBC Capital
Subscribe for More Information
07:05 EDTICPTIntercept update in-line with expectations, says Baird
Subscribe for More Information
May 19, 2015
16:23 EDTICPTOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
11:57 EDTICPTFollow-up: Intercept downgraded on lack of catalysts at BofA/Merrill
As previously reported, BofA/Merrill downgraded Intercept to Neutral from Buy. The firm said with the announcement of Intercept's Phase 3 REGENERATE trial to evaluate OCA for NASH removes a catalyst for shares. BofA/Merrill believes the focus will now turn to PBC approval and expected in 1H 2016 launch, which is reflected in valuation. The firm maintains its $315 price target.
11:46 EDTICPTIntercept downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
11:09 EDTICPTIntercept trial endpoints not surprising, says Deutsche Bank
Deutsche Bank says it is not surprised by the design or size of the Phase 3 OCA trial announced this morning. The firm has a Buy rating on Intercept with a $500 price target.
10:07 EDTICPTIntercept shares defended on trial design at Cowen
Subscribe for More Information
09:52 EDTICPTIntercept weakness a buying opportunity, says RBC Capital
Subscribe for More Information
06:32 EDTICPTIntercept to host conference call
Subscribe for More Information
06:08 EDTICPTIntercept announces international Phase 3 trial of OCA
Subscribe for More Information
May 18, 2015
20:16 EDTANFUrban Outfitters down over 16% after disappointing Q1 results
Urban Oufitters (URBN) is down sharply after reporting first quarter earnings per share and revenue that missed analyst estimates. WHAT'S NEW: Urban Oufitters reported Q1 EPS of 25c on revenue of $739.01M, below consensus expectations of 30c and $758.25M, respectively. Urban Outfitters also reported Q1 comparable retail segment net sales up 4%, with Q1 retail segment net sales increasing 17% at Free People, 5% at Urban Outfitters, and 1% at the Anthropologie Group. Wholesale segment net sales rose 18%. WHAT'S NOTABLE: On its Q1 earnings conference call, Urban Outfitters announced that Urban Outfitters Group CEO Ted Marlow, who oversaw the direction of the namesake brand, would retire at the end of August. While Urban Outfitters did not provide guidance, Urban Outfitters Anthropologie Group CEO David McCreight commented on the Anthropologie brand, "We're expecting we could see Q2 shaping up like Q1 in terms of low single-digit comps. We could also see being in the low-mid-single digit comps. It's hard to tell at this point." ANALYST REACTION: Two analyst firms lowered their respective price targets on Urban Outfitters following the company's earnings report. Sterne Agee, which rates Urban Outfitters a Neutral, lowered its 12-month price target to $34 from $46, noting the company has had trouble getting both its Urban Outfitters and Anthropologie brands to perform at the same time. Cantor, which maintained its Buy rating, lowered its price target to $53 from $54, saying that Anthropologie sales disappointed, but noting that a "later catalog release appears to us to have pushed some sales at Anthropologie into May." PRICE ACTION: Urban Outfitters fell 16.4% to just over $34 in after-hours trading. PEERS: Other publicly traded companies in the space include Abercrombie & Fitch (ANF), American Eagle (AEO), Five Below (FIVE), Pacific Sunwear (PSUN), and Zumiez (ZUMZ).
17:03 EDTNOAHNoah Holdings reports Q1 EPS 37c vs. 30c in 1Q14
Subscribe for More Information
10:36 EDTKATEKate Spade partnering with start-up on iPhone charging accesories, WSJ reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use